Business
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA. The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website
About this update from Sutro Biopharma, Inc.
[{"type":"image","alt":"Sutro Biopharma, Inc.","displaySize":"","headline":null,"caption":"Sutro Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rd31Oc6_ZbJywDRY5HheFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8","width":186,"height":55}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will present at the TD Cowen 45th Annual Health Care Conference taking place March 3-5, 2025 in Boston, MA.","length":373,"tagName":"p"},{"type":"text","content":"The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.","length":225,"tagName":"p"},{"type":"text","content":"About Sutro Biopharma Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates Sutro’s continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.","length":823,"tagName":"p"},{"type":"text","content":"Investor ContactEmily WhiteSutro Biopharma(650) 823-7681 [email protected]","length":128,"tagName":"p"},{"type":"text","content":"Media ContactAmy BonannoLyra Strategic [email protected]...